Curis, Inc. to Present CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at the 22nd European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Curis scientists and collaborators will present data from two of its proprietary drug candidates at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” held in Berlin, Germany, November 16-19, 2010.